The Forward P/E of Neuland Laboratories Limited is 19.34
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, antiemetic, central nervous system, fluoroquinolones, corticosteroids, antipsychotic, antibacterial and anti-parkinson, anti-ulcerants, and prostaglandins. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was founded in 1984 and is headquartered in Hyderabad, India.